Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05929066 · ClinicalTrials.gov registry record · Phase 3
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
A Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 2,300
- Enrollment target
- 20
- Study locations
NCT05929066: Active Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
NCT05929066 is a Phase 3 study of Obesity and Overweight that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 2,300 participants, above the 817-participant average among 1,053 other Obesity trials with a reported enrollment target (182% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05929066, a Phase 3 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Retatrutide
Study Locations (20)
Florida
- Teradan Clinical Trials, LLC - Brandon
- Suncoast Research Group - Miami
- New Horizon Research Center - Miami
- Clinical Neuroscience Solutions - Orlando
- Progressive Medical Research - Port Orange
California
- Neuro-Pain Medical Center - Fresno
- Valley Research - Fresno
- Artemis Institute for Clinical Research - San Diego
Arizona
- Central Phoenix Medical Clinic - Phoenix
- Arizona Research Center - Phoenix
Connecticut
- Yale University School of Medicine - New Haven
- Chase Medical Research, LLC - Waterbury
Georgia
- NeuroTrials Research Inc - Atlanta
- North Georgia Clinical Research - Woodstock
Illinois
- Northwestern University - Chicago
- Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative - Springfield
Arkansas
- Medical Investigations - Little Rock
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,300 participants |
| Start Date | 2023-07-10 |
| Est. Completion | 2026-05 |
| Phase | Phase 3 |
What the registry record for NCT05929066 still lists
NCT05929066 is an interventional study that assigns participants to a tested intervention. Its 2,300 participants enrollment target places it among the larger protocols in the corpus, above the 817-participant average among 1,053 other Obesity trials with a reported enrollment target (182% higher).
The record links to 4 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05929066 names 20 study sites across 10 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05929066 about?
NCT05929066 is a clinical study titled "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight". The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This...
What is the current status of trial NCT05929066?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 2,300 participants. The study started on 2023-07-10. Estimated completion is 2026-05.
What conditions does trial NCT05929066 study?
This clinical trial studies the following conditions: Obesity, Overweight, Obstructive Sleep Apnea, Osteoarthritis, Knee.
What interventions are being tested in trial NCT05929066?
The interventions under investigation include: Placebo (DRUG), Retatrutide (DRUG).
Who is sponsoring clinical trial NCT05929066?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05929066 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05929066's enrollment target sits among peer trials
2,300 40th of 1053 higher than 1,014 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04124120 · 2,300 participants · NA
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
- NCT05237258 · 2,300 participants · NA
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- NCT05732623 · 2,300 participants
Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
- NCT05759988 · 2,300 participants · NA
Cervical Ripening as an Outpatient Method Using the Foley (COMFORT)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI